Pancreatic Cancer Research

ResearcherAzienda Ospedaliera Carlo PomaNo recent work listed

Sandro Barni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7633-0378; OpenAlex author ID A5061179981. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
2
Collaborators
20
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 3 papers · 2016: none · 2017: 4 papers · 2018: none · 2019: 1 paper

Papers 11

  1. Outcome of head compared to body and tail pancreatic cancer: a systematic review and meta-analysis of 93 studies. Co-author DOI 10.21037/jgo.2018.12.08↗
  2. Borderline resectable pancreatic cancer: More than an anatomical concept. Co-author DOI 10.1016/j.dld.2016.11.010↗
  3. Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. Last author DOI 10.1016/j.ejca.2017.05.025↗
  4. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials. Last author DOI 10.1016/j.hpb.2017.07.005↗
  5. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. Last author DOI 10.1016/j.ijrobp.2016.10.030↗
  6. Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials. Last author DOI 10.1016/s1499-3872(15)60344-7↗
  7. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Last author DOI 10.1097/mpa.0000000000000314↗
  8. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Co-author DOI 10.18632/oncotarget.5197↗
  9. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Co-author DOI 10.1016/j.dld.2013.09.020↗
  10. Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis. Last author DOI 10.1016/j.dld.2014.01.001↗
  11. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Co-author DOI 10.1007/s00280-012-1875-1↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fausto Petrelli · 8 shared papers, 2014–2019 · strength 0.58
  2. Gianluca Tomasello · 3 shared papers, 2017–2019 · strength 0.26
  3. Roberto Labianca · 5 shared papers, 2012–2017 · strength 0.25
  4. Michele Ghidini · 2 shared papers, 2017–2019 · strength 0.18
  5. Stefano Cascinu · 4 shared papers, 2012–2017 · strength 0.17
  6. Antonio Costanzo · 1 shared paper, 2019 · strength 0.10
  7. Tiziana Comito · 1 shared paper, 2017 · strength 0.08
  8. Marta Scorsetti · 1 shared paper, 2017 · strength 0.08
  9. Massimo Falconi · 1 shared paper, 2017 · strength 0.07
  10. Michele Reni · 1 shared paper, 2017 · strength 0.07
  11. Stefania Mosconi · 2 shared papers, 2014–2015 · strength 0.07
  12. Rossana Berardi · 2 shared papers, 2014–2015 · strength 0.07
  13. Luca Faloppi · 2 shared papers, 2014–2015 · strength 0.07
  14. Michela Cinquini · 2 shared papers, 2014–2015 · strength 0.07
  15. Alberto Zaniboni · 2 shared papers, 2012–2015 · strength 0.07
  16. Mario Scartozzi · 1 shared paper, 2015 · strength 0.04
  17. Kalliopi Andrikou · 1 shared paper, 2015 · strength 0.04
  18. Alessandro Bittoni · 1 shared paper, 2015 · strength 0.04
  19. Francesco Di Costanzo · 1 shared paper, 2014 · strength 0.03
  20. Giuseppe Tonini · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.